Genmab A/S Stock Forecast, Price & News

+16.28 (+3.62 %)
(As of 08/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume454 shs
Average Volume945 shs
Market Capitalization$30.49 billion
P/E Ratio6.62
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive GNMSF News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

Genmab A/S logo

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Genmab A/S (OTCMKTS:GNMSF) Frequently Asked Questions

Is Genmab A/S a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Genmab A/S stock.
View analyst ratings for Genmab A/S
or view top-rated stocks.

What stocks does MarketBeat like better than Genmab A/S?

Wall Street analysts have given Genmab A/S a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Genmab A/S wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Genmab A/S?

Genmab A/S saw a drop in short interest during the month of July. As of July 15th, there was short interest totaling 6,900 shares, a drop of 13.8% from the June 30th total of 8,000 shares. Based on an average daily volume of 600 shares, the days-to-cover ratio is currently 11.5 days.
View Genmab A/S's Short Interest

When is Genmab A/S's next earnings date?

Genmab A/S is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Genmab A/S

How were Genmab A/S's earnings last quarter?

Genmab A/S (OTCMKTS:GNMSF) announced its quarterly earnings results on Wednesday, November, 5th. The company reported $0.47 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.45 by $0.02. The business earned $45.65 million during the quarter, compared to analyst estimates of $53.94 million. Genmab A/S had a trailing twelve-month return on equity of 29.09% and a net margin of 51.39%.
View Genmab A/S's earnings history

How has Genmab A/S's stock price been impacted by COVID-19 (Coronavirus)?

Genmab A/S's stock was trading at $211.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, GNMSF stock has increased by 121.0% and is now trading at $466.3575.
View which stocks have been most impacted by COVID-19

Who are Genmab A/S's key executives?

Genmab A/S's management team includes the following people:
  • Dr. Jan G.J. van de Winkel, Co-Founder, Pres & CEO (Age 60, Pay $2.83M)
  • Mr. Anthony Pagano, Exec. VP & CFO (Age 43, Pay $960.19k)
  • Mr. Anthony Mancini, Exec. VP & COO (Age 50, Pay $1.46M)
  • Mr. Peter Storm Kristensen, Director of Legal Lead Corp. & Non-Independent Director (Age 46, Pay $64.01k)
  • Dr. Judith V. Klimovsky, Exec. VP & Chief Devel. Officer (Age 63, Pay $1.15M)
  • Dr. Mijke Zachariasse Ph.D., Director of Protein Production & Chemist and Non-Independent Director (Age 47, Pay $64.01k)
  • Dr. Rima Bawarshi Nassar Ph.D., VP, Head of Global Regulatory Affairs – Oncology & Non-Independent Director (Age 68, Pay $16k)
  • Mr. Peter Ros, Sr. Director of Fin. & Accounting
  • Mr. Andrew Carlsen, Sr. Director & Head of Investor Relations
  • Ms. Birgitte Stephensen M.Sc., Sr. VP & Head of Global IPR and Legal (Age 60)

Who are some of Genmab A/S's key competitors?

What is Genmab A/S's stock symbol?

Genmab A/S trades on the OTCMKTS under the ticker symbol "GNMSF."

How do I buy shares of Genmab A/S?

Shares of GNMSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genmab A/S's stock price today?

One share of GNMSF stock can currently be purchased for approximately $466.36.

How much money does Genmab A/S make?

Genmab A/S has a market capitalization of $30.49 billion and generates $1.55 billion in revenue each year.

How many employees does Genmab A/S have?

Genmab A/S employs 871 workers across the globe.

When was Genmab A/S founded?

Genmab A/S was founded in 1999.

What is Genmab A/S's official website?

The official website for Genmab A/S is www.genmab.com.

Where are Genmab A/S's headquarters?

Genmab A/S is headquartered at KALVEBOD BRYGGE 43, COPENHAGEN G7, 1560.

How can I contact Genmab A/S?

Genmab A/S's mailing address is KALVEBOD BRYGGE 43, COPENHAGEN G7, 1560. The company can be reached via phone at 45-7020-2728 or via email at [email protected]

This page was last updated on 8/4/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.